OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2026-03-31-accounts

Annual Report 2025/26

For healthy East London lives

3

Contents

Chair and Chief Executive’s Introduction

Trustees’ Report

ees’ Report
Who we are and what we do 4
Review of 2025/26 6
Aims for 2026/27 8
Equity, Diversity and Inclusion 9
Finance review 10
Risk management 14
Structure, governance and management 16
Statement of Trustees’ Responsibilities 20

Auditor’s Report

21

Financial Statements 2025/26

cial Statements 2025/26
Statement of Financial Activities 25
Statement of Financial Position 26
Cash Flow Statement 27
Notes to the accounts 28

2

Chair and Chief Executive’s Introduction

The 2025/26 financial year was another year of strong performance for both grant-funding and investment stewardship.

In total we were delighted to award £36.1m in funding, across our three partners Barts Health NHS Trust (Barts Health), Faculty of Medicine and Dentistry (FMD) at Queen Mary University of London (QMUL) and the School of Health and Medical Sciences at City St George’s, University of London. A particular highlight was the award of £16.63m to facilitate the creation of a state-of-the-art Breast Cancer Centre at St Bartholomew’s Hospital, the fulfilment of a vision to transform breast cancer care in East London which formed part of our Barts900 campaign in 2023.

This was just one of a broad range of research and healthcare projects which we support through a number of targeted funding schemes. Some key awards this year have included:

As we enter the final year of our 2022-27 strategy, we remain on course to give £150m across the five-year period. You can find out more about how we are making a difference to the health of people in East London in our impact report (available on our website, renewed in September) and the What We Fund pages of our website.

Thanks to prudent management and strong investment performance during the year, the investment portfolio closed at £504m despite geo-political headwinds during March 2026. The Charity’s available reserves remained comfortably within the range required to support operational and grant expenditure commitments.

We could not have achieved so much in the last year without our highly talented and engaged staff, Board and advisers, partners and supporters. We feel very fortunate to have their support and would like to extend our thanks for all they do.

Fiona Miller Smith Chief Executive Officer

Stephen Bonnard Chair of Trustees

3

Who we are and what we do

Vision

Life changing improvements to health for the people of East London.

Mission

A charity with its roots in East London, dedicated to supporting improvements to healthcare and transformative research for local health benefit. We work in partnership with the NHS, local research institutes and others who can help us achieve our goals

Barts Charity Strategy 2022–2027 strategic objectives

Research

We fund high quality and innovative research that enhances our understanding of health and illness and has the potential to improve and/or save lives in East London.

Healthcare

We facilitate transformation to patient care and support for our dedicated NHS staff, primarily focusing our efforts at Barts Health.

Fundraising and communications

We are transforming our approach to fundraising to significantly grow revenue and enable us to achieve our ambitions for our mission.

We aim to inspire greater support by communicating about the people and projects we fund and the impact they make.

Endowment

We manage our endowment to ensure we take full advantage of potential opportunities to deliver our mission, now and in the future.

How we work

We set ourselves high standards for how we operate and aim to maximise the impact we make with our resources.

4

Our funding principles and focus

To achieve our funding and impact strategic objectives, we focus our funding:

Our primary focus is on our funding being relevant to, and having an impact in, East London. We expect that much of the activity we support will also have a wider health benefit, both across the UK and potentially globally.

We adhere to robust funding processes to make sure our resources can improve healthcare and support transformative research. We also strive to ensure that our funding processes and policies are inclusive and unbiased. We are a member of the Association of Medical Research Charities and can demonstrate high standards of governance around decision processes and monitoring involved in funding.

Our values

We are proud of the work we do. We have created a set of values that express who we are as a charity, the way we want to work and the culture that we want to live and breathe every day.

One Team

We work collaboratively as one team, supporting and respecting each other and embracing diverse experiences and perspectives.

Ambitious

We care passionately about Barts Charity’s mission, empowering each other to constantly improve and achieve our best.

Open

We are honest and transparent, sharing information willingly and encouraging the giving and receiving of constructive feedback.

Accountable

We take pride in doing the right thing and acting with integrity. We take ownership of our actions and learn from our mistakes.

5

Review of 2025/26

In our 2025 Annual Report we set out our strategic targets for 2025/26. Here, we summarise the progress we’ve made against these:

----- Start of picture text -----
Strategic aims FY2025/6 Progress made
Funding – Research/Healthcare delivery
Progress the creation of a Clinical Research • Contributed £16.63m to support the
Facility at The Royal London Hospital and creation of the Barts Breast Cancer Centre
consider additional ways to support improved at St Batholomew’s Hospital and
breast cancer outcomes for Barts Health
• Clinical Research Facility building approvals
patients
reached a milestone to enable progression
of build
Maintain a significant funding programme in • £36.1m granted to healthcare and
research and healthcare research projects
Maintain a pipeline of high-quality research • High-quality pipeline of short- and
and healthcare funding applications beyond long-term, as well as small and larger,
this financial year opportunities for funding research and
healthcare applications and initiatives
developed.
Develop a new open-access dissemination • Open Access Outputs Sharing Policy and
policy and refresh a policy outlining the Expected Standard of Conduct Policy
expected standard of conduct for those launched and associated processes
involved in funded activities and implement implemented.
associated processes
Fundraising and communications
Create ongoing, targeted major gift • Fundraising and Marcomms functions
fundraising portfolio from Funding & Impact became a single Fundraising & Comms team
pipeline, including the Breast Cancer Centre from November 2025
subject to approval
• Work has been undertaken to clarify the
FR&C 2027-32 strategy
• Planning undertaken for a Breast Cancer
Centre campaign to test some strategic
propositions prior to 2027
Strengthen fundraising operations to ensure • A new fundraising operations function
that our data and systems work has been created within the Fundraising
and Comms team
Grow supporter database through targeted • My ThankYou rolled out across the five
lead generation activity including introduction hospital sites
of WiFi portal acquisition at all hospital sites
• Launch of Barts Charity gateway to hospital
and rollout of My ThankYou.
WiFi portal link targeted in early FY2026/27
----- End of picture text -----

6

----- Start of picture text -----
Endowment
Continue to implement asset allocation under • Continued to progress the revised asset
our investment strategy, including following allocation, with further private market
responsible investing principles commitments and enhanced oversight of
undrawn commitments and liquidity
• Responsible investing, including ESG
integration and stewardship considerations
remain integrated into the investment
process
Develop a new Reserves Policy • Developed a new reserves policy, including
the introduction of Net Asset Value (NAV) as
the metric along with tier-based monitoring.
How we work
Commence planning for the 2027-32 strategy • Full review of existing 2022-27 strategy
undertaken
• On track to have 2027-32 strategy approved
at October 2026 Board
Consider how we resource and use technology, • Systems, data and digital (incl Artificial
data management and data analysis including Intelligence) centralised within the People
deployment of AI tools and Operations team
• Digital Landscape Review launched, reporting
June 2026
Replace current payroll service providers and • Group pension scheme moved from Aegon to
pension providers Standard Life from January 2026
• Payroll service provider review deferred
Continue to foster a fair and supportive • Recruitment of new non-execs at Board,
workplace culture, underpinned by robust Grants Committee and Investment
governance Committee
• Strong staff survey results
----- End of picture text -----

7

Some events took place during FY2025/26 which had an impact upon whether/how we fulfilled some of our key aims:

Strategic aims for 2026/27

Funding

Endowment

How we work

Fundraising and communications

8

Commitment to Equity, Diversity and Inclusion (EDI)

We remain committed to EDI initiatives because we believe that they make us a stronger organisation. We believe that our commitment to EDI is best demonstrated through action. Our EDI Commitment, Priorities and Definitions and our action plans are available in full on our website.

We ran our annual diversity survey, looking at the diversity characteristics of our staff and non-executives. The survey is based on guidelines issued by the organisation Equality, Diversity & Inclusion in Science & Health (EDIS) which draw upon a wealth of studies and research data. The questions and response categories are designed to follow the 2021 census so that we can benchmark the results. These covered age, disability/long-term health condition/impairment, ethnic group, gender, sexual orientation, and religion/belief.

There is also very low representation of people reporting a disability/long-term health condition. About half of the staff have some form of caring responsibility.

We are very conscious of the importance of diversity and inclusion across our personnel and want to ensure that our recruitment processes are not acting as a block to wider representation. A new inclusive recruitment process has been in place since January 2025 and we are monitoring whether it has the effect of increasing staff diversity over time.

We had a high response rate of 89%. For reasons of information governance, we do not store the responses, and so the survey is a snapshot of the Charity’s personnel diversity at a single point in time. As a small organisation, it can be challenging to report data about diversity in case it compromises anonymity for those who report in very low numbers. Therefore, we do not publish the results in full.

The Charity remains most unrepresentative for people identifying as Black/African/Caribbean/ Black British, especially amongst nonexecutives, although this is improving.

9

Finance review

Review of financial performance

Our financial strategy is to manage and grow our investment assets and voluntary income to support annual grant giving and operating activities for the long term. The net assets as of 31 March 2026 increased by £12m to £427m (2025: £415m).

In reviewing the performance of our investments, we consider the total return of the portfolio, both income and capital. By showing the total return, which combines both income generated by our assets and the associated capital gains/losses, as opposed to separating these out, we see the full picture of our finances.

We use this concept as a basis for addressing the two basic principles of our financial strategy:

Managing the endowment

The management of the endowment is designed to provide financing, alongside voluntary income, for our funding programme. The assets in the portfolio are selected based on the prospects of value accretion in the long run. A managed approach to risk is taken and the Trustees and management work with advisers to provide an appropriate balance of risk against a targeted return.

The Trustees have delegated investment decision-making to the Investment Committee. The Investment Committee appoints and monitors investment advisers to assist them in managing both financial and property elements of the portfolio. It meets quarterly and reports back to the Trustee board after each meeting.

Based on a review of our investment beliefs, a revised investment strategy was formulated in 2022. The strategy aims to diversify the overall sources of risk and return and includes selling down the directly owned property portfolio.

The Statement of Financial Activities shows that, during the financial year, the charity received income of £13m, (2025: £12.9m), of which £9.8m was unrestricted (2025: £10.7m). Gains on investment assets were £40m (2025: £19.2m). Total Charitable expenditure increased over the same period to £35.4m (2025: £21.4m) . The proportion of non-charitable activities spending relative to total expenditure decreased to 11.66% (2025: 17.96%). The decrease in the ratio was primarily on account of the increase in charitable expenditure during the year compared to the previous year.

As stated above, and as shown in the Statement of Financial Position, the charity’s net assets were £427m (2025: £415m). The endowment funds increased in value due to realised and unrealised gains during the year. General funds have decreased due to charitable expenditure in the year. Restricted funds have remained stable year on year.

10

Investment review

The Investment portfolio recorded gains of £40m during the year. The value of the charity’s investments decreased by £2.4m to £504m over the 12-month period to 31 March 2026 primarily due to withdrawal to fund charitable expenditure. The majority of equity markets delivered strong positive returns over the 12-month period to 31 March 2026, with emerging market equities outperforming developed market equities. Returns within fixed income markets were also positive despite the volatility in yields during the period.

At the beginning of the second quarter of 2025, US tariff uncertainty fuelled concerns regarding both the growth and inflation outlook, as well as the potential impact on fiscal and monetary policy. However, these tariff-related concerns eased during May and June. In the third quarter, some central banks were prompted to cut interest rates as markets were driven by the resilience of economic growth, with equities continuing to rally.

In the fourth quarter, economic resilience and ongoing AI led optimism drove financial markets, supported by abating risks from tariffs and trade, and despite uncertainty resulting from regional politics. However, in the first quarter of 2026 economic optimism was offset by geopolitical tensions between US and Iran. Escalation of the war led to a sharp spike in energy prices over March, which increased inflation expectations and stoked fears of other second-round effects.

During the month of March, equity and bond markets produced negative returns on account of geopolitical tensions in the Middle East. Despite that, returns for the twelve-month period to 31 March 2026 remained healthy.

The long-term target for the portfolio is an average total return of Consumer Price Index (CPI) +4.5% per year (net of fees) over a rolling three-year period and an annualised return in excess of the portfolio’s blended benchmark.

The Charity underperformed the broader market during the financial year, with the portfolio returning 8.3% net of fees, versus the blended benchmark return of 13.0%. The blended benchmark has a higher allocation to public market equities than the actual portfolio, and public market equities returned 17.8% over the last 12 months.

Though the long-term target for the portfolio is a total annualised return of CPI +4.5% over rolling three-year periods, the Investment Committee recognises that, given the high inflationary environment over recent years, this will be a challenging target to achieve over the shorter term.

Investment performance is monitored quarterly by our Investment Committee with the assistance of our investment advisors, Mercer, who provide advice and monitoring services for the financial portfolio.

----- Start of picture text -----
All figures are in Return Target Target
% per annum achieved CPI+4.5% Blended Benchmark
3-year period to 31 7.3% 7.7% • 10.6%
March 2026
3-year period to 31 4.1% 10.0% • 4.6%
March 2025
Since inception to 8.3% 7.6% • 6.6%
31 March 2026
----- End of picture text -----

11

Reserves

The Charity holds assets in funds, each type of which dictates how the funds may be disbursed:

Endowment funds: there are a number of segregated individual permanent endowments which are usually created in the form of a trust that limits the use of both the original capital and any investment gains attached to them. There is also an aggregated expendable endowment fund – these funds, and gains arising from them, can be applied generally by the Trustees to deliver the Charity’s objectives. The value of the aggregated expendable endowment, as at 31 March 2026, was £367m (2025: £329.6m).

Restricted funds: are amounts given with a restriction agreed between the donor and the Charity that specifies the area of the Charity’s work that will be supported. Barts Charity has a large number of these funds supporting the many areas of the Barts Health NHS Trust’s work.

All other funds held by the Charity form the general funds. However, Trustees may choose (and have chosen) to set aside designated funds to make sure a particular objective is given prominence. Trustees may remove a designation if they choose.

Reserves policy

Given the nature of the Charity’s activities and our grant-making strategy, the Trustees have determined that the reserves policy, taken in conjunction with spending and long-term investment policies, is intended to deliver the following objectives:

For these objectives, the Trustees consider reserves to be best reflected by the Charity’s net asset value (NAV), incorporating both the investment portfolio and outstanding grant commitments. This provides a more complete measure of the Charity’s available financial capacity and long-term sustainability.

The Charity sets a tiered reserves target, updated annually for inflation, which is intended to maintain the real value of the portfolio over time rather than on a strict year-by-year basis.

This approach allows the Charity to absorb short to medium-term market volatility without requiring reactive changes to grant-making. The Trustees monitor performance against this target using a range-based framework to support decision-making over time. As at 31 March 2026, the inflation-adjusted reserves target was £415m (2025: £401m).

The level of total reserves (on a NAV basis) as at 31 March 2026 was £427m (2025: £415m). The Trustees therefore consider that the Charity has sufficient resources to continue its charitable activities into the future.

In addition, the Trustees monitor liquidity to ensure that the Charity can meet its obligations as they fall due. The policy requires that at least 50% of the investment portfolio is held in liquid assets, supporting the timely funding of grant commitments and reducing the need for asset sales in adverse market conditions.

The reserve, spending and long-term investment policies are reviewed at least annually and adjusted if necessary.

12

Responsible investing

Barts Charity believes that it is right to consider environmental, social, and governance (ESG) factors in investment decisions, in order to identify material risks as well as to earn sustainable, long-term returns. The Charity also recognises that long-term sustainability issues, including climate change, present risks and opportunities that increasingly may require explicit consideration. We believe that it is possible to invest with a positive impact without reducing investment returns. Areas of particular interest include improving societal healthcare outcomes.

As a result, ESG (including but not limited to climate change) and stewardship considerations are integrated in the investment process. This includes selecting new investment managers and monitoring the existing ones, and an ongoing review of the portfolio’s ESG characteristics compared to relevant benchmarks and peers. During the year under review, Barts Charity also reviewed the voting and engagement activities of the listed equity managers.

Going concern statement

The preparation of the accounts for the year ending 31 March 2026 has been undertaken on the basis that Barts Charity is a going concern.

As part of the assessment of the going concern basis of the Charity, scenario analysis and a multi-year projection of reserve levels has been undertaken. This has demonstrated that the Charity is expected to hold sufficient assets to meet its reserve policy levels, as set out above. Our portfolio is sensitive to movements in investment values, but it still has sufficient liquidity to enable the charity to meet its obligations and is able to meet its planned grant commitments without being a forced seller of assets. Based on these assessments, the Trustees have determined the Charity to be a going concern and the basis of the preparation of the annual report and accounts on a going concern basis is therefore appropriate.

When we appoint new investment managers, the Charity believes it is important to consider the level of diversity, including (but not limited to) gender across the manager’s investment team. The Charity has no direct investments in tobacco stocks. The Charity monitors exposure to tobacco through pooled funds, including passive index trackers as well as actively managed strategies, aiming to have less than 1% of equities in tobacco companies (i.e. approximately half or less vs the aggregated equity benchmark).

We have a strategic equity exposure achieved through investment in pooled equity funds. The Charity has made an allocation to a Sustainable Global Equity Fund. This aims to provide a positive tilt across a broad range of ESG factors, including reducing carbon emissions, relative to investment in a traditional global equity fund. We follow the principles set out in the Charity Commission’s guidance (CC14) and ensure our investment decisions align with our ethical standards.

13

Public benefit

The Trustees confirm that they have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing Barts Charity’s aims and objectives and in planning future activities and setting the grant-making policy for the year. The Trustees consider that our charitable activities for the improvement of healthcare are all for the public benefit.

Fundraising policy

We aim to fundraise in a way that is compelling, respectful and in keeping with our values.

The Charity is registered with the Fundraising Regulator and is committed to adhering to the Code of Fundraising Practice. We are also members of the Institute of Fundraising and refer to their best practice guidance. Our own practice and policies make sure that no individual, including vulnerable people, are put under undue pressure to make a donation. In the year to 31 March 2026, 1,627 people and organisations supported us through donations or fundraising and we received no complaints related to fundraising. We regularly review our privacy statement in line with the UK General Data Protection Regulation (UK GDPR). This and our complaints policy are freely available on our website.

Risk management

Our Trustees have adopted a Risk Management Policy and regularly review the major risks to which Barts Charity is exposed. The risks and mitigations are recorded in risk registers which are reviewed regularly by the senior management team and the Finance and Audit Committee and by Investment Committee and Board as appropriate.

The major strategic risks and principal mitigations on 31 March 2026 are set out below.

----- Start of picture text -----
Risk Actions to manage risk
Funding • Strong stakeholder and sector engagement
Financial and demand pressures, alongside to understand impact and likelihood
changing strategic focus and external of pressures, how they affect funding
environments, for NHS and University programme and maintain open dialogue and
research sector impacts partner ability to partnership with Barts Health, QMUL and
develop funding cases for support and, in the others as plans and strategies develop and
longer term, support sustainability of projects the external environment shifts.
supported.
Fundraising • Introduce new philanthropy proposition
Economic pressures, with continued cost of supported by new Fundraising & Comms
living challenges and investment volatility – Advisory Committee
individuals/corporations may be less able or • Move to develop relationships based upon
willing to give funding pipeline, supported by multi-year
campaigns
Communications • Regular communications with Barts Health
A more politicised environment around NHS Trust senior team.
healthcare funding and cost pressures may • Close relations with Barts Health’s
cause us reputational risk by association. communications teams.
• Regular dialogue with potential major donors.
----- End of picture text -----

14

----- Start of picture text -----
Risk Actions to manage risk
Endowment • Investments are spread across diverse asset
Period of market volatility means that the classes, reducing risk and strengthening the
endowment does not generate the target portfolio against market fluctuations.
annual return and potentially results in a fall • Part of the portfolio has been allocated to
in value of the portfolio. property, private debt, and fixed income that
provide steady contractual income
• Investments are made with a long-term
view. The charity has a buffer above the
minimum reserve level and can withstand
periods of lower return without impacting the
operations or funding.
How we work • Cyber Security Review led by external
We suffer financial/reputational loss as a consultant being undertaken in FY2026/27
result of a cyber security incident/data breach. • Additional cyber security safeguards have
been put in place in partnership with our
Technology partners. Penetration testing
of technology infrastructure is carried out
regularly
• Information Governance framework review
completed and strengthened
• Ongoing organisation-wide approach to
adoption of AI tools
----- End of picture text -----

15

Structure, governance and management

Constitution

Barts Charity is a company limited by guarantee (registration number 07168381) and a registered charity in England and Wales (registration number 212563). It is governed by Articles of Association most recently updated on 12 December 2016. It is fully independent of the Department of Health and Social Care and regulated only by the Charity Commission.

The Board has assessed its governance against the Charity Commission’s Governance Code for larger charities and is pleased to report high levels of compliance against the suggested standards. An area of continued focus for the Board is to ensure that the Charity is representative of its grantees and the communities it serves across both staff and non-executives.

Charitable purposes

Our charitable purposes relate to hospital services (including research), or to any other part of the health service associated with any hospital as our Trustees think fit. In practice, we focus our support for improvement and innovation in healthcare on the Barts Health group of hospitals and FMD. We also support the School of Health & Medical Sciences at City St George’s, University of London. We carefully consult with representatives of our grantee organisations to make sure they are aligned with our strategic priorities and to secure the greatest impact from our funding. But we retain our independence to act in the best interests of Barts Charity and the community we serve.

Non-executives and committees

Barts Charity acts through its Board of Directors (who are known as Trustees). As of 31 March 2026, there were 10 Trustees. Since then, one Trustee has reached the end of their term, one has stepped down and one has joined. All Trustees give of their time freely and no Trustee remuneration is paid. Details of Trustee expenses and related transactions are disclosed in Notes 12 and 13 to the accounts. Trustees are required to disclose all relevant interests and register them with the Company Secretary and, in accordance with the Charity’s policy, withdraw from decisions where a conflict of interest arises.

Power to appoint new Trustees lies with the existing Board, in accordance with the provisions of our Articles of Association. All Trustees are appointed for a fixed term of not more than three years, renewable to a maximum of nine years in total. Exceptionally, the Board may decide to extend this maximum term for a Trustee in appropriate circumstances.

The Board has established a series of committees so that much of the Charity’s detailed governance work can be conducted by groups of Trustees and specialist members with the most relevant experience and expertise. Committee membership is confirmed annually. Specialist committee members who aren’t Trustees are appointed annually, renewable up to a total term of five years. All new Trustees and committee members have an induction programme which enables them to become familiar with key constitutional and operating documents, meet senior Trustees and management, and tour the hospitals that we work with.

16

The Board and each committee conduct an annual review of their performance in accordance with the Charity’s Performance Review Policy against a checklist of questions. These cover matters such as objects, terms of reference, relationship with executive, documentation, conduct of meetings and skill set.

The Board has established a Scientific Review Panel to supplement the peer review of research grant applications. We are fortunate to be able to call on a team of eminent scientists from across the UK with appropriate expertise relative to the subject matter of the applications. They meet to discuss the full applications and submit their views and recommendations to the Grants Committee for its consideration. Final decision-making authority rests with the Grants Committee for funding requests up to £650,000 and with the Board for requests over this amount.

In addition, the Charity Executive has established Everyday Impact and Advancing Healthcare Panels comprising Barts Health staff members to support our Everyday Impact Grant and Advancing Healthcare Small Grant funding schemes. The Panels provide real-world experience and review of healthcare applications under these schemes which provide grants of up to £50,000. Final decision-making authority rests with the Executive for funding requests in these schemes.

We review all staff salaries every year taking into consideration inflation and data from comparable foundations and the wider third sector. We check the proposed increase against the benchmark for each role to ensure that annual pay awards stay in line with the market. Increases are applied from 1 April each year. The Charity reserves the discretion not to award an increase, especially when an employee’s salary is already at the top of their benchmark range. The same principles apply to the pay of the SMT, which is approved by the Appointments & Remuneration Committee.

Pension

The Charity operates a non-contributory individual money-purchase scheme for all eligible members of staff, contributing the equivalent of 10% of pensionable salary to each employee’s fund. Employees can additionally choose to make employee contributions to their pension as a deduction from their salary with a salary sacrifice option. The scheme is fully compliant with autoenrolment regulations.

Management arrangements

The Trustees delegate the management of the charity to the staff team led by the Chief Executive and the Senior Management Team (SMT). The Chief Executive has been in post since May 2016.

Staff remuneration

Staff remuneration is closely scrutinised to ensure that we can attract and retain the best talent, while keeping salaries aligned with the market. When we introduce a new role or undertake a mid-year pay review, we use a live salary database run by specialist reward consultants to reference the benchmark salary range for the role. The benchmark is compiled using a number of factors. These include comparable sectors, the nature and seniority of the role (job rank), our location, number of employees and turnover. We use the range from median to upper quartile mean.

17

Reference and administrative details for Barts Charity

Registered and principal office

12 Cock Lane London EC1A 9BU

Company registered number: 07168381 Charity registered number: 212563

Non-executives

Includes changes up to date of signing

Trustees

Stephen Bonnard, Chair Ian Hart, Deputy Chair (to 31 December 2025), Senior Independent Trustee (from 1 January 2026) Prof Sarah Purdy OBE, Deputy Chair (from 1 January 2026) Davoud Amel-Azizpour (from 1 April 2026) Sally Flanagan (to 31 May 2025) Prof Catherine Godson Dr Richard Lewis Dr Ultan McDermott (from 1 June 2026) Jean Murphy Nimesh Patel (to 31 March 2026) Frances Prenn (from 1 January 2026) Dr Lorna Williamson OBE (to 31 March 2026) Prof Ian Jacobs (ex officio Trustee, Chair of Barts Health NHS Trust)

Appointments and Remuneration Committee

Stephen Bonnard, Chair Ian Hart Nimesh Patel (to 31 March 2026) Prof Sarah Purdy OBE (from 1 May 2026)

Finance and Audit Committee

Nimesh Patel, Chair Davoud Amel-Azizpour (Chair Elect, from 1 April 2026) Ian Hart

Dr Richard Lewis Mohammad Memon Ayo Ajayi (from 1 May 2026) Dr Naila Nielsen (from 1 May 2026)

Grants Committee

Dr Lorna Williamson OBE, Chair (to 31 March 2026)

Prof Sarah Purdy OBE, Chair (from 1 April 2026) Prof Theodoros Arvanitis (from 1 January 2026) Dr Shera Chok (from 1 January 2026) Prof Mirela Delibegovic Prof Catherine Godson

Dr Ultan McDermott Prof Elizabeth Sapey (from 1 January 2026) Prof Kanchan Rege Thrasher

Investment Committee

Sally Flanagan, Chair (to 31 May 2025) Ian Hart, Chair (from 1 June 2025) Stephen Bonnard Andy Bruce (to 31 March 2025) Philip Glaze (to 30 November 2025) Jean Murphy Nikhil Chandra (from 1 September 2025) Will Riley (from 1 September 2025) Julian Sinclair (from 1 September 2025)

18

Senior Management Team

Fiona Miller Smith, Chief Executive Fiona Bickley, Chief Operating Officer Victoria King, Director of Funding & Impact Jay Longworth, Director of Fundraising & Communications (from 1 November 2025) Ilia Ralphs, Director of Fundraising (to 25 June 2025) Prabhakar Sundaresan, Chief Financial Officer

Advisers

Bank

National Westminster Bank plc 1 Princes Street London EC2R 8BP

Auditor

Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP

Legal Advisers Broadfield UK LLP One Bartholomew Close London EC1A 7BL

Property Advisers

Swiss Life Asset Managers UK Ltd 55 Wells Street London W1T 3PT

Workman LLP 80 Cheapside London EC2V 6EE

Investment Advisers

Mercer 1 Tower Place West Tower Place EC3R 5BU

Global Custodian

The Northern Trust Company 50 Bank Street Canary Wharf London E14 5NT

Insurance Brokers

Willis Towers Watson Ltd 51 Lime Street London EC3M 7DQ

Taylor Wessing LLP 5 New St Square Holborn London EC4A 3TW

Hogan Lovells International LLP Atlantic House Holborn Viaduct London EC1A 2FG

Wedlake Bell LLP 71 Queen Victoria Street London EC4V 4AY

Anderson Financial Management Ltd Saville Court 11 Saville Place Bristol BS8 4EJ

19

Statement of Trustees’ responsibilities

The charity trustees (who are also the directors of Barts Charity for the purposes of company law) are responsible for preparing a trustees’ annual report, strategic report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing the financial statements, the trustees are required to:

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Statement as to disclosure to our auditors

In so far as the trustees are aware at the time of approving our trustees’ annual report:

This Trustees’ report, incorporating the Strategic Report, was approved by the

Board of Trustees of Barts Charity on 6 July 2026 and signed on its behalf.

Stephen Bonnard

Chair of Trustees Date: 6 July 2026

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

20

Independent auditor’s report to the members of Barts Charity

Opinion

We have audited the financial statements of Barts Charity (’the charitable company’) for the year ended 31 March 2026 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 ‘’The Financial Reporting Standard Applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

21

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the trustees’ annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the trustees’ responsibilities statement set out on page 20, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

22

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through

designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

23

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Luke Holt (Senior Statutory Auditor)

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

6th Floor 9 Appold Street London EC2A 2AP

Date: 23/07/2026

24

Statement of Financial Activities

(incorporating an income and expenditure account) for the financial year ended 31 March 2026

Unrestricted Restricted Endowment 2026 Total 2025 Total
funds funds funds funds funds
Note £'000 £'000 £'000 £'000 £'000
Income and
endowments from:
Donations and legacies 2.1 713 3,214 - 3,927 3,201
Investments 2.2 9,084 - - 9,084 9,693
Total income 9,797 3,214 - 13,011 12,894
Expenditure on:
Raising funds 3.1 5,878 - - 5,878 7,521
Charitable activities 3.1 34,178 1,227 - 35,405 21,404
Total expenditure 40,056 1,227 - 41,283 28,925
Net expenditure
before gains/(losses) (30,259) 1,987 - (28,272) (16,031)
on investments
Gains/(losses) on
investment assets
7.2 6,756 - 33,283 40,039 19,227
Net income/
(expenditure)
(23,503) 1,987 33,283 11,767 3,196
Transfers between funds 10 2,320 (1,972) (348) - -
Gains/(losses) on
revaluation of heritage 6 - - - - 180
assets
Net movement in funds (21,183) 15 32,935 11,767 3,376
Fund balances brought
forward at 1 April 2025
67,324 11,905 335,746 414,975 411,599
Fund balances carried
forward at 31 March 2026
46,141 11,920 368,681 426,742 414,975

All activities relate to continuing activities. The Notes on pages 28 to 47 form part of these financial statements.

25

Statement of Financial Position

as at 31 March 2026

Unrestricted Restricted Endowment 2026 Total 2025 Total
funds funds funds funds Funds
Note £'000 £'000 £'000 £'000 £'000
Fixed assets
Tangible fxed assets 5a 21 - - 21 60
Intangible fxed assets 5b - - - - -
Heritage assets 6 - - 17,489 17,489 17,489
Investments 7 140,921 11,920 351,192 504,033 506,480
Total fxed assets 140,942 11,920 368,681 521,543 524,029
Current assets
Debtors 8.1 2,050 - - 2,050 2,206
Cash at bank and in hand 8.2 56 - - 56 268
Total current assets 2,106 - - 2,106 2,474
Creditors: amounts
falling due within one 9 (96,907) - - (96,907) (111,528)
year
Net current liabilities (94,801) - - (94,801) (109,054)
Total net assets 46,141 11,920 368,681 426,742 414,975
Funds
Endowment funds 10.1 - - 368,681 368,681 335,746
Restricted income funds 10.2 - 11,920 - 11,920 11,905
Unrestricted funds
Designated funds 10.3 122 - - 122 122
General funds 10.3 46,019 - - 46,019 67,202
Total funds 46,141 11,920 368,681 426,742 414,975

Steve Bonnard Nimesh Patel Chair of Trustees Chair of Finance and Audit Committee

Date: 6 July 2026

Company registration number 07168381.

The Notes on page 28 to 47 form part of these financial statements.

26

Cash Flow Statement

for the year ended 31 March 2026

for the year ended 31 March 2026
2026 2025
Note £'000 £'000
Cash fows from operating activities:
Net cash generated by / (used in) operating activities 11.1 (27,346) 21,049
Cash fows from investing activities:
Dividends, interest and rents from investments 9,084 9,693
Payments to acquire investment assets (135,049) (129,333)
Receipts from sales of investment assets 140,596 108,811
Net withdrawals from/(receipts into) investments 12,503 (10,029)
Net cash provided by / (used in) investing activities 27,134 (20,858)
Change in cash and cash equivalents in the year (212) 191
Cash and cash equivalents at the beginning of the year 268 77
Cash and cash equivalents at the end of the year 11.2 56 268

The Notes on page 28 to 47 form part of these financial statements.

27

Financial statements

for the financial year ended 31 March 2026 Notes to the accounts

1. Accounting policies

Barts Charity is a private company limited by guarantee and does not have share capital. The liability of members is limited to £1.

It is a charitable company registered in England (company number 07168381, charity number 212563) and its registered office is 12 Cock Lane, London, EC1A 9BU.

The following accounting policies have been used consistently in dealing with items which are considered material to the charity’s financial statements.

A. Accounting convention

The financial statements have been prepared under the historic cost convention, with the exception of investments and heritage assets, which are included at market value.

The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities issued in October 2019, the Financial Reporting Standard 102 applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006 and the Charities Act 2011. The Charity constitutes a public benefit entity as defined by FRS 102.

These financial statements are presented in pounds sterling (GBP), as that is the currency in which the majority of the charity’s transactions are denominated. The financial statements are presented rounded to the nearest thousand pounds.

B. Going concern

The preparation of the accounts for year ended 31 March 2026 has been undertaken on the basis that Barts Charity is a going concern. The Charity currently meets day to day working capital requirements through planned liquidation of investments.

In conjunction with the Charity’s investment advisors modelling has been undertaken incorporating stable asset values and net spending over the next three years.

This has demonstrated that the Charity is expected to hold sufficient assets to meet its liquidity requirements. Whilst the Charity’s portfolio is sensitive to movements in investment values, it still has sufficient liquidity to meet its obligations and can meet its planned grant commitments without being a forced seller of assets.

Based on these assessments the Trustees have not identified any material uncertainties relating to going concern. The Trustees have therefore determined the Charity to be a going concern and the basis of the preparation of the annual report and accounts on a going concern basis is therefore appropriate.

C. Accounting estimates and judgements

In preparing the financial statements, the Trustees have made judgements, estimates and assumptions that affect the application of the Charity’s accounting policies and the reported assets, liabilities, income and expenditure and the disclosures made in the financial statements. These estimates and judgements are continually reviewed and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The key judgements and estimates are:

a.Valuation of property

A full property valuation is undertaken triannually with an annual desktop valuation in the years between. A full property valuation was completed for 2023/24 by Knight Frank LLP, Chartered Surveyors, (refer to Note 1, Section J). The valuation has been prepared using a fair value basis, being the price that would be received to sell an asset, in an orderly transaction, between market participants at the measurement date.

28

b. Valuation of private equity and private credit investments

Due to the nature of private investments, there is no quoted market price for the funds. The value at the balance sheet date is deemed to be the most recent valuation from the private investment group, adjusted for those cashflows up to and including the balance sheet date. This is then reviewed in light of valuations which become available post the balance sheet date up to the date the financial statements are approved.

c. Allocation of income, expenses and gains/losses to restricted and endowment funds

Expenses are charged on an actual basis for restricted and endowment funds.

Donation income is charged to restricted funds on an actual basis. Investment income is charged to the relevant funds in relation to the endowment funds on a proportionate basis.

Gains and losses are allocated across all funds types on a proportionate basis on the value of the funds at the start of the year.

d. Heritage assets

Heritage Assets are not depreciated but are revalued every five years. The last valuation was completed by Gurr Johns in January 2024. Any surplus or deficit on revaluation is credited or debited to the Statement of Financial Activities.

D. Fund structure

a. Restricted funds

These are funds for which a legal restriction exists over their use and related income is restricted to the purpose of the fund.

b. Endowment funds

c. Unrestricted funds

These funds and their related income are available for use at the discretion of the Trustees for general charitable purposes relating to the following:

i. General

Sections 220(3) and 220(5) and paragraph 10(1) of Schedule 4 of the National Health Service Act 2006: To hold the property on trust for such purposes relating to hospital services (including research), or to any other part of the health service associated with any hospital, as the person holding the property thinks fit.

ii. Designated

The Trustees have chosen to earmark these funds for specific areas within the general charitable purposes.

E. Income

Income is recognised when the Charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are accounted for as income when received.

Legacy income is recognised when three criteria are met: entitlement is established, receipt of the income is probable and it can be reliably measured. Where legacies have been notified to Barts Charity and the criteria for income recognition have not been met, the legacy is treated as a contingent asset and disclosed, if material.

Rental income from investment properties is reported as operating leases and the lease incentives are amortised on a straight-line basis.

i.Permanent endowment funds

These are funds where the capital is held in perpetuity, but the related income may be used for unrestricted or restricted purposes, as specified by the donor.

Investment income is accrued at the year-end where dividends or distributions have been declared in relation to the reporting period but not received.

ii.Expendable endowment funds

These funds represent donations received by the hospitals of Barts Health NHS Trust prior to 5 July 1948 (the date on which the NHS was established). The income and capital are available for such expenditure related to sections 220(3) and 220(5) and paragraph 10(1) of Schedule 4, of the National Health Service Act 2006 (see c(i) below).

29

F. Expenditure

All expenditure is accounted for on an accruals basis. Direct costs of raising funds, charitable activities and support costs are charged to the relevant category or activity, according to the area to which the expenditure relates. Support costs incurred that relate to more than one cost category are apportioned, based on full time equivalent staff numbers in each area. Charitable activities include grants that have been approved during the year.

G. Grant commitments

Grant commitments are recognised when the following conditions have been fulfilled: (1) the receipt of necessary approvals for the grant from the Trustees, and (2) the communication of the approval to the grant recipient. Grants are discounted to reflect the time value of money, if this is considered material to the financial statements.

H. Fixed assets

Fixed assets (tangible or intangible) are capitalised when a separable asset can be identified with a value of £10,000 or more (exclusive of irrecoverable VAT), and where the estimated useful life of the asset (without the need for additional spend) can be estimated as three years or more.

a. Tangible fixed assets

Tangible fixed assets are included in the Statement of Financial Position at cost less accumulated depreciation. Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and any impairments are shown as reducing both the initial cost and brought forward depreciation.

Depreciation is charged on a straight line basis to support costs over their estimated useful lives. Fixtures, fittings and equipment are depreciated over the shorter of five years or the remaining lease term for the office premises.

b.Intangible fixed assets

Intangible fixed assets are included in the Statement of Financial Position at cost less accumulated amortisation. Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, and any impairments are shown as reducing both the initial cost and

brought forward amortisation.

Amortisation is charged on a straight line basis to support costs over their estimated useful lives. IT software is considered to have a useful life of five years.

I. Heritage Assets

Heritage assets are capitalised and include: art collections, historic archives, sculptures, ceramic surgical instruments, uniforms, teaching materials, and other items.

They are reported on the balance sheet at their insured values, which are based on replacement values in the retail market or, where appropriate, in the second-hand retail market with items of a similar nature, age, condition and quality.

They are not depreciated but are revalued every five years, with the last valuation completed by Gurr Johns in January 2024.

Any surplus or deficit on revaluation is credited or debited to the Statement of Financial Activities. Assets are reviewed regularly for significant damage and appropriate remedial works are carried out wherever possible to preserve the assets or prevent further deterioration.

J. Investments

Quoted investments are stated at market value at the year-end date. Asset purchases and sales are recognised at the date of trade. Unquoted pooled financial investments are valued based on the number of units held and the price per unit provided by the custodian or fund manager.

These net asset valuations are calculated independently by third party administrators and are subject to annual audit. Private investments are held through funds managed by private investment groups. As there is no identifiable market price for private investment funds, these funds are included at the most recent valuations from the private investment groups and adjusted for cash flows if the valuation is not available at the balance sheet date.

Market valuations of Barts Charity’s investment properties were carried out in accordance with the current editions of the Royal Institution of Chartered Surveyors (RICS) Valuation – Global Standards, incorporating the International Valuation Standards and the RICS UK National Supplement.

30

The valuations were carried out by Knight Frank LLP, Chartered Surveyors, who were instructed as our external valuer to value Barts Charity’s freehold and long leasehold interests at 31 March 2024. They reported their opinion of the aggregate of the values of Barts Charity’s interest in the individual buildings. For the years ended 31 March 2025 and 31 March 2026 a desktop valuation was completed by Barts Charity with advice from our property advisors.

K. Realised and unrealised gains and losses on investment assets

Realised and unrealised gains and losses on investment assets are included in ‘gains and losses on investment assets’ within the Statement of Financial Activities.

L. Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at their fair value, net of transaction costs, and are measured subsequently at amortised cost, using the effective interest method, less any impairment.

Long term debtors are defined as fully recoverable amounts outstanding for more than 12 months at the balance sheet date.

M. Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

N. Cash

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of a change in value.

The Statement of Financial Activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The Charity does not acquire put options, derivatives or other complex financial instruments directly. Where individual investment managers have discretion to use financial instruments, valuation is in line with market practice.

P. Pension contributions

The cost of employer contributions to the NHS Pension Scheme and the Defined Contribution Scheme are charged to the Statement of Financial Activities.

Certain past and present employees are covered by the provisions of the NHS Pensions Scheme. Details of benefits payable under these provisions can be found on the NHS Pensions Website (www.nhsbsa.nhs.uk/nhs-pensions). The scheme is an unfunded, defined benefit scheme, preparing its own statements, that covers NHS employers, general practices and other bodies allowed under the direction of the Secretary of State, in England and Wales. The Scheme is not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, the scheme is accounted for as if it were a defined contributions one: the cost to an NHS body of participating in the scheme is taken as equal to the contributions payable to the scheme. Applicable rates for employee contributions for the NHS Pension Scheme was 12.5% for 2025/26 (unchanged for 2024/25). Employer contributions were 14.38% for both 2025/26 and 2024/25.

Employees employed after 1 April 2011 can choose to belong to a Defined Contribution Scheme which is a Group Personal Pension Scheme. For the year ended 31 March 2026, the rates of employer contribution for the Defined Contribution Scheme were 10% for all staff (10% for SMT and 8% for other staff from the year ended 31 March 2025). Employee contributions are voluntary.

O. Financial instruments

Basic financial instruments are initially recognised at their transaction value and subsequently measured at their fair value, as at the balance sheet date using the closing quoted market price.

31

Financial statements

for the financial year ended 31 March 2026

Notes to the accounts

2. Income

2.1 Income from donations and legacies

Year ended 31 March 2026 Unrestricted Restricted Endowment 2026 Total
income income income income
£'000 £'000 £'000 £'000
Donations 456 1,409 - 1,865
Legacies 257 643 - 900
Trading income - 9 - 9
Government grants - 1,153 - 1,153
Total 2026 713 3,214 - 3,927

In addition to the legacy income recognised above, Barts Charity is aware of legacies totalling approximately £25k (£237k in 2024/25) which do not meet the SORP recognition criteria at the year end, but are expected to become receivable in future years.

Government grants received during the year relates to income received from the Department for Health and Social Care in support of Early Career Researchers. All conditions of the grants have been fulfilled. The income has been fully spent in the year.

Year ended 31 March 2025 Unrestricted Restricted Endowment 2025 Total
income income income income
£'000 £'000 £'000 £'000
Donations 563 1,337 - 1,900
Legacies 461 836 - 1,297
Trading income - 4 - 4
Total 2025 1,024 2,177 - 3,201

2.2 Income from investments

Year ended 31 March 2026 Unrestricted Restricted Endowment 2026 Total
income income income income
£'000 £'000 £'000 £'000
Investment properties 942 - - 942
Investments listed on stock
exchanges
3,774 - - 3,774
Private investments 3,915 - - 3,915
Interest on cash held as part of
the investment portfolio
453 - - 453
Total 2026 9,084 - - 9,084

32

Year ended 31 March 2025 Unrestricted Restricted Endowment 2025 Total
income income income income
£'000 £'000 £'000 £'000
Investment properties 2,886 - - 2,886
Investments listed on stock
exchanges
3,491 - - 3,491
Private investments 2,930 - - 2,930
Interest on cash held as part of the
investment portfolio
386 - - 386
Total 2025 9,693 - - 9,693

33

3. Expenditure

3.1 Total expenditure

3. Expenditure
3.1 Total expenditure
Year ended 31 March 2026 Costs of Charitable Support Total
Expenditure
raising funds expenditure costs 2026
£'000 £'000 £'000 £'000
Direct expenditure
Grants – Research - 15,239 - 15,239
Grants – Service delivery - 21,345 - 21,345
Grants written back – Research - (1,913) - (1,913)
Grants written back –
Service delivery
- (1,712) - (1,712)
Non-grant charitable expenditure - 50 - 50
Costs of raising funds
Financial and property investment 2,878 - - 2,878
Fundraising 194 - - 194
Total direct expenditure 3,072 33,009 - 36,081
Staff and support costs
Salaries, social security and
pension costs
941 837 1,587 3,365
Other staff and related costs 32 5 71 108
Marketing and communications - - 207 207
Legal, accounting and IT - 43 508 551
Offce costs - - 554 554
Grant administration - 31 7 38
Irrecoverable VAT 159 2 218 379
Subtotal staff and other costs 1,132 918 3,152 5,202
Allocation of staff and overheads 1,674 1,478 (3,152) -
Total 5,878 35,405 - 41,283
Unrestricted Restricted Endowment 2026 Total
expenditure expenditure expenditure expenditure
£'000 £'000 £'000 £'000
Costs of raising funds 5,878 - - 5,878
Charitable expenditure 34,178 1,227 - 35,405
Total 2026 40,056 1,227 - 41,283

34

3. Expenditure

3.1 Total expenditure (continued)

Year ended 31 March 2025 Costs of Charitable Support Total
Expenditure
raising funds expenditure costs 2025
£'000 £'000 £'000 £'000
Direct expenditure
Grants – Research - 17,333 - 17,333
Grants – Service delivery - 4,867 - 4,867
Grants written back – Research - (1,480) - (1,480)
Grants written back – Service
delivery
- (1,525) - (1,525)
Costs of raising funds
Financial and property investment 4,364 - - 4,364
Fundraising 240 - - 240
Total direct expenditure 4,604 19,195 - 23,799
Staff and support costs
Salaries, social security and pension
costs
1,015 863 1,480 3,358
Other staff and related costs 41 17 71 129
Marketing and communications - - 167 167
Legal, accounting and IT - 52 527 579
Offce costs - - 558 558
Grant administration - 13 - 13
Loss on disposal of heritage assets - 4 - 4
Irrecoverable VAT 171 7 140 318
Subtotal staff and other costs 1,227 956 2,943 5,126
Allocation of staff and overheads 1,690 1,253 (2,943) -
Total 7,521 21,404 - 28,925
Unrestricted Restricted Endowment 2025 Total
expenditure expenditure expenditure expenditure
£'000 £'000 £'000 £'000
Costs of raising funds 7,521 - - 7,521
Charitable expenditure 20,999 401 4 21,404
Total 2025 28,520 401 4 28,925

Although Barts Charity maintains regular contact with grant-holders, there are occasions when planned expenditure is not achievable and the related grant accrual is reversed.

35

3.2 Direct charitable expenditure by institution

3.2 Direct charitable expenditure by institution
2026 2025
Total Total
£'000 £'000
Barts Health NHS Trust 22,170 5,010
Faculty of Medicine & Dentistry at Queen Mary University London 13,388 16,615
School of Health and Medical Sciences at City St George's, University of London 554 86
Grant funded activity 36,112 21,711
Direct other spending 523 489
Writebacks (3,625) (3,005)
Total direct charitable expenditure 33,010 19,195

4. Employees

4.1 Analysis of staff costs

4. Employees
4.1 Analysis of staff costs
2026 2025
Total Total
£'000 £'000
Salaries and wages 2,679 2,753
Social security costs 417 365
Other pension costs 270 240
Total 3,366 3,358
Average number of full-time equivalents 43 44
Average head count 44 46

Staff costs include termination payments of £104,344 to 4 employees (£78,274 to 5 employees in 2024/25).

Of the above, termination payments to key management personnel totalled £54,867 to 1 employee in 2025/26 (£Nil to zero employees in 2024/25).

36

4.2 Higher paid employees

The following number of employees received emoluments falling within the ranges indicated:

Number of employees Value of pension Value of pension Number of staff in Number of staff in
contributions receipt of pension
contributions
2026 2025 2026
2025
2026 2025
£'000 £'000
£60,000 to £70,000 2 4 13 20 2 4
£70,001 to £80,000 1 5 8 29 1 5
£80,001 to £90,000 2 - 12 - 2 -
£90,001 to £100,000 - - - - - -
£100,001 to £110,000 - 1 - 15 - 1
£110,001 to £120,000 1 1 16 16 1 1
£120,001 to £130,000 2 1 25 12 2 1
£130,001 to £140,000 - 1 - 13 - 1
£210,001 to £220,000 1 1 21 21 1 1

Key management personnel (the senior management team of the charity) received aggregate employee benefits of £876,268 in 2025/26 (£867,625 in 2024/25).

5. Operational fixed assets

5a. Tangible fixed assets

5b. Tangible fixed assets

At cost
Offce equipment
£’000
As at 1 April 2025
166
Additions
-
Disposals
-
Balance at 31 March 2026
166
Depreciation:
As at 1 April 2025
106
Disposals in the year
-
Charge for the year
39
Balance at 31 March 2026
145
Net book value at:
31 March 2026
21
31 March 2025
60
At cost
Software
£’000
As at 1 April 2025
214
Additions
-
Disposals
-
Balance at 31 March 2026
214
Amortisation:
As at 1 April 2025
214
Disposals in the year
-
Charge for the year
-
Balance at 31 March 2026
214
Net book value at:
31 March 2026
-
31 March 2025
-

37

6. Heritage assets

2026 2025 2024 2023 2022
£'000 £'000
Valuation at start of the year 17,489 17,313 16,600 16,600 16,600
Additions – donations - 180 - - -
Disposals - (4) (1,057) - -
Revaluation - - 1,770 - -
Valuation at end of year 17,489 17,489 17,313 16,600 16,600
Type of heritage assets:
Antique furniture 792 792 796 1,253 1,253
Paintings, prints and drawings 11,020 11,020 10,840 8,792 8,792
Books and manuscripts 2,669 2,669 2,669 3,003 3,003
Other 3,008 3,008 3,008 3,552 3,552
Total 17,489 17,489 17,313 16,600 16,600

Paintings, prints and drawings include two William Hogarth paintings which have been valued at £4m and £3.5m respectively (£4m and £3.5m in 2024/25). Other heritage assets include clocks, barometers, works of art, sculptures, ceramics, glass, silver and gold. Heritage Assets are not depreciated but are revalued every five years with the last valuation completed by Gurr Johns, auctioneers and valuers, in January 2024.

All heritage assets at 31 March 2026 are included within the endowment fund (31 March 2025: all heritage assets are included within the endowment fund).

38

7. Investments

7. Investments
7.1 Analysis of fxed asset investments
Property Financial 2026 Total 2025 Total
Fixed asset investments £'000 £'000 £'000 £'000
Market value at 1 April 41,585 464,895 506,480 519,929
Less: Disposals at cost (11,000) (129,596) (140,596) (108,811)
Add: Acquisitions at cost - 135,049 135,049 129,333
Net gain/(loss) on revaluation or
disposal of investment assets
(2,500) 18,103 15,603 (44,000)
Net cash receipts into/
(withdrawals from) theportfolio
- (12,503) (12,503) 10,029
Total 28,085 475,948 504,033 506,480
2026 Total 2025 Total
Market value at 31 March: £'000 £'000
Investment properties 28,085 41,585
Investments listed on stock exchanges 347,001 340,776
Private investments 124,647 107,535
Short term investments 4,300 16,584
Total 504,033 506,480

Short term investments are held within the investment portfolio, predominantly to fund private investment capital calls and are shown separately in the table above, to distinguish from other investments.

Financial investments held at 31 March 2026 include 12 unit trust funds, representing 74% of the total value, and 40 separate private investments (in 2024/25 14 unit trust funds representing 76% and 38 separate private investments).

At the year end, Barts Charity had undrawn commitments to private equity funds of £80.4m, which are expected to be called at various future dates, whilst the current investments in private equity funds will be expected to be realised by a return of capital. The carrying value of the private equity investments of £125m reported above represents the valuations of the funds at 31 March 2026, as provided by relevant fund managers and/or as computed by our global custodian. However, it is not possible for the Trustees to liquidate these investments prior to the future return of capital.

7.2 Analysis of gains and losses on revaluation and disposal of investment assets

Unrestricted Restricted Endowment 2026 Total
Funds Funds Funds
Year ended 31 March 2026 £'000 £'000 £'000 £'000
Gains/(losses) on revaluation and
disposal of fnancial investments
6,998 - 34,476 41,474
Gains/(losses) on revaluation and
disposal ofpropertyinvestments
(242) - (1,193) (1,435)
Other currency gains - - - -
Total 6,756 - 33,283 40,039

39

Unrestricted Restricted Endowment 2025 Total
Funds Funds Funds
Year ended 31 March 2025 £'000 £'000 £'000 £'000
Gains/(losses) on revaluation and
disposal of fnancial investments
166 - 16,924 17,090
Gains/(losses) on revaluation and
disposal ofpropertyinvestments
21 - 2,116 2,137
Other currency gains - - - -
Total 187 - 19,040 19,227

An analysis of gross income arising from the investment assets is set out in Note 2.2.

8. Current assets

8.1 Analysis of debtors

8. Current assets
8.1 Analysis of debtors
2026 2025
£'000 £'000
Trade debtors 125 630
Prepayments 313 190
Accrued income 1,473 1,310
Other debtors 139 76
Total 2,050 2,206

All debtors at 31 March 2026 relate to unrestricted funds (31 March 2025: all debtors relate to unrestricted funds).

Accrued income largely relates to income on financial investments and amortisation of a rent free period for related leases (see Note 1, Section E).

Included within accrued income is an amount of £0.1m which relates to rent amortisation due to be released after more than one year (31 March 2025: £0.1m).

8.2 Cash at the bank and in hand

2026 2025
£'000 £'000
Cash in UK clearing bank accounts 56 268

40

9. Creditors due in one year

9. Creditors due in one year
2026 2025
Amounts falling due within one year: £'000 £'000
Trade creditors 97 188
Other creditors - 258
Taxation and social security 124 120
Grant accruals 96,185 110,134
Accruals and deferred income 501 828
Total 96,907 111,528

As our grant awards do not give us an unconditional right to defer disbursements, all grant creditors are shown as due within one year. However, based on past experience, the grants are active for longer than one year.

Deferred income represents rent billed to tenants in advance for the first quarter of the following financial year.

fnancial year.
2026 2025
£'000 £'000
Deferred income brought forward at 1 April 298 541
Income deferred during the year 452 1,869
Income released during the year (689) (2,112)
Deferred income carried forward at 31 March 61 298

41

10. Funds

10.1 Funds – Year ended 31 March 2026

Balance as Income Expenditure Transfers Gains and Balance
at 1 April (Losses) as at 31
2025 March
2026
Endowment funds £'000 £'000 £'000 £'000 £'000 £'000
Edward Hewlett 3,012 - - (3,012) - -
Hannington 1,187 - - (1,187) - -
Hamblen Thomas 370 - - - 37 407
MacCready Mann 365 - - - 37 402
Levy Family 315 - - - 32 347
MAEL Jones 293 - - - 29 322
Ablett 207 - - (207) - -
Funds < £200k 384 - - (237) 15 162
Expendable endowments 329,613 - - 4,295 33,133 367,041
Total endowment funds 335,746 - - (348) 33,283 368,681
Restricted funds
Margaret Centre 917 22 (58) - - 881
Gastroenterology 645 - (105) - - 540
IBD Research 631 - 12 - - 643
Whipps Cross General 552 4 (164) 6 - 398
Funds <£500k 9,160 3,188 (912) (1,978) - 9,458
Total restricted funds 11,905 3,214 (1,227) (1,972) - 11,920
Unrestricted funds
Designated funds
Cardiac funds 122 - - - - 122
Total designated funds 122 - - - - 122
General funds 67,202 9,797 (40,056) 2,320 6,756 46,019
Total unrestricted funds 67,324 9,797 (40,056) 2,320 6,756 46,141
Total funds 414,975 13,011 (41,283) - 40,039 426,742

42

10.2 Funds – Year ended 31 March 2025

Balance as Income Expenditure Transfers Gains and Balance
at 1 April (Losses) as at 31
2024 March
2025
Endowment funds £'000 £'000 £'000 £'000 £'000 £'000
Aylwen Bursaries 3,497 - - (3,497) - -
Edward Hewlett 2,872 - - - 140 3,012
Hannington 1,132 - - - 55 1,187
Hamblen Thomas 353 - - - 17 370
MacCready Mann 348 - - - 17 365
Levy Family 300 - - - 15 315
MAEL Jones 279 - - - 14 293
Funds < £200k 564 - - - 27 591
Expendable endowments 385,682 - (4) (75,000) 18,935 329,613
Total endowment funds 395,027 - (4) (78,497) 19,220 335,746
Restricted funds
Margaret Centre 951 16 (50) - - 917
Gastroenterology 645 - - - - 645
IBD Research 905 - (274) - - 631
Funds <£500k 10,104 2,161 (77) (2,476) - 9,712
Total restricted funds 12,605 2,177 (401) (2,476) - 11,905
Unrestricted funds
Designated funds
Cardiac funds 122 - - - - 122
Funds <£100k - - 10 (10) - -
Total designated funds 122 - 10 (10) - 122
General funds 3,845 10,717 (28,530) 80,983 187 67,202
Total unrestricted funds 3,967 10,717 (28,520) 80,973 187 67,324
Total funds 411,599 12,894 (28,925) - 19,407 414,975

43

10.3 Funds - additional

Endowment funds

Note 1, Section D provides further details of the permanent endowment fund structure. There were no other income, expenditure or transfers in 2025/26. Expenses have not been charged to the permanent endowment funds. Due to the historic nature of these, there is no certainty that the terms of the trust of the endowed gift would allow this. In conjunction with ongoing works to consider the provenance of these funds, we continue to review this methodology.

Restricted funds

Note 1, Section D provides further details of the restricted fund structure. There was no allocation of investment income or expenses to the funds in 2025/26, given that they are funded from readily available cash. The Charity is continuing a review of its restricted funds at hospital sites. The target is to consolidate these into fewer funds with more flexible purposes at each site in order to promote more effective expenditure. This work is ongoing.

Details of significant restricted funds

Name of fund

Nature and purpose of fund

Margaret Centre Provision of palliative care at the Margaret Centre (Whipps Cross Hospital) Gastroenterology Gastroenterology unit (Whipps Cross Hospital) IBD Research Research into Crohn’s disease Whipps Cross General Any purpose at Whipps Cross Hospital

Details of significant designated funds

Name of fund

Nature and purpose of fund

Cardiac Investigation and treatment of heart diseases including the advancement of scientific and medical education and research

Expenditure will be made from a restricted or designated fund when a grant award is made that meets the criteria of the relevant restriction or designation.

Transfers between funds

Transfers between funds represent:

44

10.4 Prior year distribution of net assets

Unrestricted Restricted Endowment Total
funds funds funds
£'000 £'000 £'000 £'000
Tangible assets 60 - - 60
Intangible assets - - - -
Heritage assets - - 17,489 17,489
Investments 176,318 11,905 318,257 506,480
Total fxed assets 176,378 11,905 335,746 524,029
Debtors 2,206 - - 2,206
Cash at bank and in hand 268 - - 268
Total current assets 2,474 - - 2,474
Creditors: amounts falling due
within oneyear
(111,528) - - (111,528)
Net current liabilities (109,054) - - (109,054)
Total net assets 67,324 11,905 335,746 414,975

11. Notes to the cash flow statement

11.1 Net cash used in operating activities

11. Notes to the cash fow statement
11.1 Net cash used in operating activities
2026 2025
Amounts falling due within one year: £'000 £'000
Net (expenditure) / income for the year 11,767 3,376
Adjustments for:
Losses/(Gains) on revaluation and disposal of investment assets (15,603) 44,000
Losses/(Gains) on revaluation and disposal of heritage assets - (180)
Investment income (9,084) (9,693)
Depreciation charges 39 39
Loss on disposal of heritage assets - 4
Change in debtors 156 (510)
Change in creditors (14,621) (15,987)
Cash outfow from operating activities (27,346) 21,049
11.2 Analysis of changes in cash and cash equivalents
2025 Movement 2026
£'000 £'000 £'000
Cash in hand and at the bank 268 (212) 56

45

12. Trustee transactions

12. Trustee transactions
2026 2025
£ No £ No
Trustee travel, subsistence and hospitality expenses 4,153 3 2,088 2

Premiums for Trustee indemnity insurance were paid by the Charity on the part of Trustees totalling £8,400 (2024/25: £11,194).

13. Related party transactions

The total amount of related party donations made without conditions was £3,240 (2024/25: £7,767).

The total amount of related party donations made with conditions was £50,000 (2024/25: £Nil).

During the year Barts Charity made revenue and capital grants (net of writebacks) to Barts Health NHS Trust of £20.0m (2024/25: £3.1m).

14. Operating leases

14.1 Operating lease income

Barts Charity generates income from leasing out space within its investment properties. The future minimum lease payments receivable under non-cancellable operating leases are:

2026 2025
£'000 £'000
Not later than one year 237 881
Later than one year and not later than fve years 236 566
Later than fve years 246 -
719 1,447

14.2 Operating lease commitments

Barts Charity was committed to making the following payments under non-cancellable operating leases:

operating leases:
2026 2025
£'000 £'000
Not later than oneyear 122 245
Later than one year and not later than fve years 2 124
124 369

46

15. Net income for the year

15. Net income for the year
2026 2025
£'000 £'000
This is stated after charging:
Auditors' remuneration – audit fees 67 63
Auditors' remuneration – non-audit fees 1 3
Amortisation - -
Depreciation 39 39
Operating lease payments 246 246

47

Barts Charity Ground Floor 12 Cock Lane London EC1A 9BU

E: hello@bartscharity.org.uk

T: 020 7618 1717 Registered charity no. 212563 Registered company no. 07168381

www.bartscharity.org.uk

48